But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

A major international study led by researchers at University College London has found that semaglutide, the active ingredient ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

Dow Jones Top Company Headlines at 9 PM ET: Amazon Shares Surge on 13% Revenue Jump, Strong Cloud Sales | Apple ... The e-commerce giant said Amazon Web Services is growing at its fastest rate since ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

Roblox posted a wider third-quarter loss but boosted its revenue forecast for the year as a pair of videogaming crazes generated robust top-line growth. Fox logged higher revenue in its fiscal first ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...